A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223 in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
Epistemonikos ID: 0b71202716679db347dca8401ee9eabcea4a80d7
First added on: May 04, 2024